In 2020, the US Food and Drug Administration (FDA) approved brexucabtagene autoleucel (Tecartus) which is a CD19 targeting CAR-T cell therapy for the treatment of MCL assessed in the ZUMA-2 clinical trial [11]. Here, CD19 is linked to mantle cell lymphoma.